Research graph
References from Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis. Local targets link to admitted publications; unresolved targets remain external evidence.
Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis.
10.1016/s1474-4422(19)30151-6 · 2019 · External reference
New drugs for multiple sclerosis: new treatment algorithms.
10.1097/wco.0000000000001063 · 2022 · External reference
Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
10.1007/s00415-022-11193-w · 2022 · External reference
How patients with multiple sclerosis acquire disability.
10.1093/brain/awac016 · 2022 · External reference
New horizons for multiple sclerosis therapy: 2025 and beyond.
10.1002/ana.27270 · 2025 · External reference
Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis.
10.1056/nejmoa1601277 · 2017 · External reference
Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
10.1212/wnl.0000000000010376 · 2020 · External reference
Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials.
10.1111/ene.14823 · 2022 · External reference
Five-year safety and efficacy outcomes with ofatumumab in patients with relapsing multiple sclerosis.
10.1007/s40120-025-00784-0 · 2025 · External reference
Five years of ublituximab in multiple sclerosis: ULTIMATE I and II open-label extension study.
10.1001/jamaneurol.2026.0007 · 2026 · External reference
Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis.
10.1007/s00415-015-7978-y · 2016 · External reference
Paradigm shifts: early initiation of high-efficacy disease-modifying treatment in multiple sclerosis.
10.1177/13524585211033190 · 2021 · External reference
Early aggressive treatment approaches for multiple sclerosis.
10.1007/s11940-021-00677-1 · 2021 · External reference
High-efficacy therapies for treatment-naïve individuals with relapsing-remitting multiple sclerosis.
10.1007/s40263-022-00965-7 · 2022 · External reference
Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies.
10.1001/jamaneurol.2021.2738 · 2021 · External reference
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.
10.1002/ana.22366 · 2011 · External reference
CONSORT 2025 statement: updated guideline for reporting randomized trials.
10.1001/jama.2025.4347 · 2025 · External reference
Multiple sclerosis and cancer incidence: a Danish nationwide cohort study.
10.1016/j.msard.2018.12.014 · 2019 · External reference
Lifespan normative data on rates of brain volume changes.
10.1016/j.neurobiolaging.2019.05.010 · 2019 · External reference
Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging.
10.1177/13524585231162586 · 2023 · External reference
Pregnancy and infant outcomes in women with multiple sclerosis treated with ocrelizumab.
10.1212/nxi.0000000000200349 · 2025 · External reference
Comparison between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation.
10.1001/jamaneurol.2023.1542 · 2023 · External reference
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
10.1177/13524585241267211 · 2024 · External reference
Defining reliable disability outcomes in multiple sclerosis.
10.1093/brain/awv258 · 2015 · External reference
Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario.
10.1007/s10072-024-07449-0 · 2024 · External reference
Real world study of ocrelizumab in multiple sclerosis: Kuwait experience.
10.1016/j.msard.2023.104941 · 2023 · External reference
Relapses in multiple sclerosis: relationship to disability.
10.1016/j.msard.2015.09.002 · 2016 · External reference
Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy.
10.1002/1531-8249(199907)46:1<79::aid-ana12>3.0.co;2-9 · 1999 · External reference
Black holes in multiple sclerosis: definition, evolution, and clinical correlations.
10.1111/j.1600-0404.2009.01221.x · 2010 · External reference
Ocrelizumab in early-stage relapsing-remitting multiple sclerosis: the phase IIIb ENSEMBLE 4-year, single-arm, open-label trial.
10.1212/wnl.0000000000210049 · 2024 · External reference
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
2022 · External reference
Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: real-world experience of two Swiss multiple sclerosis centers.
10.1016/j.msard.2024.105570 · 2024 · External reference
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
10.1016/s1474-4422(20)30067-3 · 2020 · External reference
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5?years.
10.1177/13524585221079731 · 2022 · External reference
Serious safety events in rituximab-treated multiple sclerosis and related disorders.
10.1002/acn3.51136 · 2020 · External reference
Serious infections in patients with relapsing and progressive forms of multiple sclerosis: a German claims data study.
10.1016/j.msard.2022.104245 · 2022 · External reference
Infection-related health care utilization among people with and without multiple sclerosis.
10.1177/1352458516681198 · 2017 · External reference
Infections in patients diagnosed with multiple sclerosis: a multi-database study.
10.1016/j.msard.2020.101982 · 2020 · External reference
Comparable infection risk of ocrelizumab and rituximab in multiple sclerosis in a nationwide Swedish cohort study.
10.1002/ana.78286 · 2026 · External reference
Comparative safety profiles of ocrelizumab and rituximab in multiple sclerosis treatment using real-world evidence.
10.1002/ana.78033 · 2026 · External reference
Immunosenescence in multiple sclerosis: new insights and clinical implications.
10.1177/13524585251367611 · 2025 · External reference
Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials.
10.1177/17562864241277736 · 2024 · External reference
Public health surveillance with electronic medical records: at risk of surveillance bias and overdiagnosis.
10.1093/eurpub/ckt044 · 2013 · External reference
Impact of disease-modifying therapies on pregnancy outcomes in multiple sclerosis: a prospective cohort study from the German multiple sclerosis and pregnancy registry.
2024 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
